The objective of this study is to evaluate the efficacy of fluidotherapy primarily on function and quality of life, secondarily on pain, morning stiffness, grip strength, and disease activity in patients with rheumatoid hand.Ninety-three patients were enrolled in this prospective, single-blind, randomized, and controlled trial. Patients were randomized into 2 groups. Group 1 (n=47) had fluidotherapy (5 times per week, for 3-week duration) and Group 2 (n=46) was the control group. All patients received joint protection and exercise program. The primary outcome measures were Health Assessment Questionnaire (HAQ) and Duruöz Hand Index (DHI) and secondary outcome measures were pain and morning stiffness assessed using the Visual Analog Scale (VAS, 0-100 mm), the Grip Ability Test (GAT), Disease Activity Score-28 (DAS-28), and grip strength. These assessments were performed at baseline, at week 3 and week 12 after treatment.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Enrollment
93
fluidotherapy and joint protection and exercise
joint protection and exercise
Health Assessment Questionnaire (HAQ)
Time frame: Change from Baseline, Health Assessment Questionnaire score at 3 weeks and 12 weeks
Duruöz Hand Index (DHI)
Time frame: Change from Baseline. Duruöz Hand Index score at 3 weeks and 12 weeks
pain
Visual Analog Scale (VAS, 0-100 mm)
Time frame: baseline, at week 3 and week 12
stiffness
Visual Analog Scale (VAS, 0-100 mm)
Time frame: baseline, at week 3 and week 12
Grip Ability Test (GAT)
Time frame: baseline, at week 3 and week 12
Disease Activity Score-28 (DAS-28)
Time frame: baseline, at week 3 and week 12
grip strength
Jamar measure
Time frame: baseline, at week 3 and week 12
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.